 Mark Abzug
Concepts (408)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 21 | 2019 | 164 | 3.120 |
Why?
| | HIV Infections | 27 | 2022 | 2459 | 2.070 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2017 | 260 | 1.870 |
Why?
| | Pneumococcal Vaccines | 5 | 2021 | 140 | 1.790 |
Why?
| | Antiviral Agents | 11 | 2021 | 654 | 1.610 |
Why?
| | Pregnancy Complications, Infectious | 14 | 2015 | 296 | 1.580 |
Why?
| | Enterovirus | 9 | 2019 | 72 | 1.330 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2021 | 540 | 1.120 |
Why?
| | Immunologic Memory | 3 | 2013 | 313 | 1.070 |
Why?
| | Pneumococcal Infections | 3 | 2013 | 96 | 1.020 |
Why?
| | Immunization, Secondary | 4 | 2021 | 85 | 1.010 |
Why?
| | Oxadiazoles | 4 | 2015 | 32 | 0.930 |
Why?
| | Paralysis | 4 | 2018 | 67 | 0.810 |
Why?
| | Child | 54 | 2023 | 19129 | 0.730 |
Why?
| | Sinusitis | 7 | 2013 | 175 | 0.670 |
Why?
| | Triazoles | 2 | 2018 | 134 | 0.650 |
Why?
| | Vaccination | 4 | 2017 | 1222 | 0.640 |
Why?
| | Mucositis | 1 | 2018 | 20 | 0.640 |
Why?
| | Anti-Retroviral Agents | 8 | 2022 | 208 | 0.640 |
Why?
| | Meningoencephalitis | 1 | 2017 | 24 | 0.620 |
Why?
| | Myelitis | 4 | 2019 | 88 | 0.610 |
Why?
| | Antibodies, Bacterial | 4 | 2013 | 126 | 0.600 |
Why?
| | Influenza, Human | 5 | 2015 | 554 | 0.600 |
Why?
| | Theilovirus | 4 | 2000 | 6 | 0.580 |
Why?
| | Encephalitis | 1 | 2017 | 129 | 0.550 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2015 | 140 | 0.550 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 216 | 0.550 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 12 | 0.530 |
Why?
| | Neonatal Sepsis | 1 | 2015 | 4 | 0.530 |
Why?
| | Central Nervous System Viral Diseases | 4 | 2019 | 63 | 0.530 |
Why?
| | Immunocompromised Host | 5 | 2021 | 200 | 0.520 |
Why?
| | Herpes Simplex | 4 | 2017 | 90 | 0.510 |
Why?
| | Disease Outbreaks | 6 | 2019 | 322 | 0.500 |
Why?
| | Influenza Vaccines | 3 | 2015 | 500 | 0.500 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 112 | 0.480 |
Why?
| | Placenta | 6 | 2000 | 639 | 0.470 |
Why?
| | CD4 Lymphocyte Count | 8 | 2022 | 267 | 0.460 |
Why?
| | Infant, Newborn | 25 | 2018 | 5255 | 0.460 |
Why?
| | Humans | 87 | 2023 | 118974 | 0.460 |
Why?
| | Neuromuscular Diseases | 3 | 2019 | 90 | 0.460 |
Why?
| | Child, Preschool | 27 | 2022 | 9491 | 0.450 |
Why?
| | Adolescent | 35 | 2022 | 18480 | 0.440 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.440 |
Why?
| | Measles Vaccine | 1 | 2012 | 17 | 0.440 |
Why?
| | Infant | 26 | 2020 | 8293 | 0.430 |
Why?
| | Mucormycosis | 3 | 2005 | 20 | 0.430 |
Why?
| | Female | 61 | 2022 | 61565 | 0.410 |
Why?
| | RNA, Viral | 12 | 2013 | 572 | 0.410 |
Why?
| | Male | 52 | 2022 | 57801 | 0.410 |
Why?
| | Anti-HIV Agents | 5 | 2022 | 664 | 0.390 |
Why?
| | Cardiovirus Infections | 2 | 2000 | 3 | 0.390 |
Why?
| | Meningococcal Vaccines | 2 | 2012 | 49 | 0.380 |
Why?
| | Candidemia | 2 | 2023 | 6 | 0.370 |
Why?
| | Viral Vaccines | 2 | 2009 | 90 | 0.370 |
Why?
| | Oxazoles | 4 | 2015 | 31 | 0.370 |
Why?
| | Viral Load | 7 | 2017 | 419 | 0.360 |
Why?
| | Candidiasis, Invasive | 2 | 2023 | 5 | 0.350 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 46 | 0.350 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2015 | 113 | 0.350 |
Why?
| | Bacterial Vaccines | 1 | 2009 | 60 | 0.330 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2008 | 16 | 0.320 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.310 |
Why?
| | Communicable Diseases, Emerging | 1 | 2008 | 28 | 0.310 |
Why?
| | Poliomyelitis | 2 | 1997 | 30 | 0.310 |
Why?
| | Mycetoma | 2 | 2004 | 5 | 0.300 |
Why?
| | Viremia | 5 | 2021 | 132 | 0.290 |
Why?
| | Rhinitis | 3 | 2009 | 129 | 0.290 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1997 | 128 | 0.290 |
Why?
| | Fetus | 3 | 2000 | 690 | 0.290 |
Why?
| | Pregnancy | 16 | 2021 | 5691 | 0.270 |
Why?
| | Antifungal Agents | 4 | 2023 | 134 | 0.260 |
Why?
| | Antibodies, Viral | 5 | 2022 | 542 | 0.260 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 1510 | 0.260 |
Why?
| | Enterovirus B, Human | 3 | 2001 | 24 | 0.250 |
Why?
| | Meningitis, Viral | 2 | 2004 | 22 | 0.250 |
Why?
| | Maxillary Sinusitis | 2 | 2004 | 8 | 0.240 |
Why?
| | Maus Elberfeld virus | 3 | 1993 | 5 | 0.240 |
Why?
| | Global Health | 2 | 2018 | 310 | 0.230 |
Why?
| | Cytomegalovirus | 2 | 2016 | 144 | 0.230 |
Why?
| | Interferon-gamma | 2 | 2015 | 736 | 0.220 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2017 | 224 | 0.220 |
Why?
| | Placenta Diseases | 2 | 1995 | 14 | 0.220 |
Why?
| | Fetal Diseases | 3 | 2000 | 148 | 0.210 |
Why?
| | Centralized Hospital Services | 1 | 2001 | 6 | 0.210 |
Why?
| | Oseltamivir | 2 | 2012 | 11 | 0.200 |
Why?
| | Pneumonia, Viral | 2 | 2021 | 348 | 0.200 |
Why?
| | Hepatitis, Viral, Human | 1 | 2001 | 26 | 0.200 |
Why?
| | United States | 13 | 2021 | 12555 | 0.200 |
Why?
| | Colorado | 7 | 2021 | 4196 | 0.200 |
Why?
| | Retrospective Studies | 14 | 2022 | 12978 | 0.200 |
Why?
| | Research Support as Topic | 1 | 2001 | 114 | 0.190 |
Why?
| | Streptococcus pneumoniae | 3 | 2014 | 141 | 0.190 |
Why?
| | Ethmoid Sinusitis | 1 | 1999 | 1 | 0.180 |
Why?
| | Young Adult | 14 | 2017 | 10793 | 0.180 |
Why?
| | Hydrops Fetalis | 1 | 1999 | 14 | 0.180 |
Why?
| | Uterine Diseases | 1 | 1999 | 14 | 0.180 |
Why?
| | Intracranial Hemorrhages | 1 | 2000 | 77 | 0.180 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 116 | 0.180 |
Why?
| | Polymerase Chain Reaction | 4 | 2016 | 1012 | 0.170 |
Why?
| | Embryonic Development | 1 | 2000 | 118 | 0.170 |
Why?
| | Drug Resistance, Microbial | 1 | 1999 | 67 | 0.170 |
Why?
| | Follow-Up Studies | 8 | 2022 | 4596 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2001 | 208 | 0.170 |
Why?
| | Mastoiditis | 2 | 2014 | 6 | 0.170 |
Why?
| | Fluoxetine | 1 | 2018 | 47 | 0.160 |
Why?
| | Enterovirus D, Human | 2 | 2018 | 76 | 0.160 |
Why?
| | Nervous System Diseases | 2 | 2019 | 261 | 0.160 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2009 | 11 | 0.160 |
Why?
| | Double-Blind Method | 3 | 2015 | 1687 | 0.160 |
Why?
| | Arboviruses | 1 | 2017 | 9 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 827 | 0.160 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1284 | 0.160 |
Why?
| | HIV-1 | 2 | 2015 | 776 | 0.160 |
Why?
| | Hospitals, Pediatric | 1 | 2001 | 505 | 0.160 |
Why?
| | Nucleic Acid Hybridization | 6 | 1991 | 193 | 0.160 |
Why?
| | Biliary Atresia | 1 | 2020 | 224 | 0.160 |
Why?
| | In Situ Hybridization | 4 | 2000 | 311 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 56 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2018 | 136 | 0.150 |
Why?
| | Treatment Outcome | 9 | 2020 | 9342 | 0.150 |
Why?
| | Allografts | 1 | 2018 | 135 | 0.150 |
Why?
| | Acyclovir | 2 | 2015 | 105 | 0.150 |
Why?
| | Sexual Maturation | 1 | 2017 | 51 | 0.150 |
Why?
| | Postoperative Complications | 2 | 2016 | 2235 | 0.150 |
Why?
| | Endoscopy | 1 | 1999 | 272 | 0.150 |
Why?
| | Immunization, Passive | 1 | 1997 | 81 | 0.150 |
Why?
| | Risk Factors | 11 | 2023 | 9000 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1440 | 0.150 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 13 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2001 | 969 | 0.150 |
Why?
| | Brain | 3 | 2017 | 2490 | 0.150 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 187 | 0.140 |
Why?
| | Adult | 17 | 2022 | 31512 | 0.140 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 228 | 0.140 |
Why?
| | Adoption | 1 | 2016 | 38 | 0.140 |
Why?
| | Nasal Mucosa | 2 | 2009 | 97 | 0.140 |
Why?
| | Hyperlipidemias | 1 | 2017 | 128 | 0.140 |
Why?
| | DNA, Viral | 2 | 2016 | 356 | 0.140 |
Why?
| | Mice, Inbred ICR | 4 | 1997 | 111 | 0.140 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1384 | 0.140 |
Why?
| | Congenital Abnormalities | 2 | 2010 | 74 | 0.140 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 99 | 0.140 |
Why?
| | Sexually Transmitted Diseases | 1 | 2017 | 155 | 0.130 |
Why?
| | Child Development | 2 | 2017 | 410 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 76 | 0.130 |
Why?
| | Ganciclovir | 1 | 2015 | 46 | 0.130 |
Why?
| | Lymphopenia | 1 | 2015 | 48 | 0.130 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 31 | 0.130 |
Why?
| | Oropharynx | 1 | 2015 | 41 | 0.130 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 525 | 0.130 |
Why?
| | Cranial Nerve Diseases | 1 | 2015 | 42 | 0.130 |
Why?
| | Incidence | 6 | 2017 | 2424 | 0.130 |
Why?
| | Adenovirus Infections, Human | 2 | 1991 | 14 | 0.130 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2015 | 60 | 0.120 |
Why?
| | Cohort Studies | 6 | 2023 | 5116 | 0.120 |
Why?
| | Rectum | 1 | 2015 | 157 | 0.120 |
Why?
| | Mycoses | 1 | 2014 | 69 | 0.120 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 26 | 0.120 |
Why?
| | Beclomethasone | 1 | 1993 | 26 | 0.120 |
Why?
| | Puberty, Delayed | 1 | 2013 | 5 | 0.120 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 157 | 0.120 |
Why?
| | Antibody Affinity | 1 | 2013 | 55 | 0.120 |
Why?
| | Giant Cells | 1 | 1993 | 22 | 0.110 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2013 | 37 | 0.110 |
Why?
| | Candida | 1 | 2012 | 35 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2020 | 847 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 187 | 0.110 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 37 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 984 | 0.110 |
Why?
| | Viral Plaque Assay | 1 | 2012 | 24 | 0.110 |
Why?
| | Hospital Design and Construction | 1 | 1992 | 3 | 0.110 |
Why?
| | Neutralization Tests | 1 | 2012 | 66 | 0.110 |
Why?
| | Chickenpox | 1 | 1993 | 100 | 0.110 |
Why?
| | Aircraft | 1 | 1992 | 28 | 0.110 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 98 | 0.110 |
Why?
| | Bacterial Infections | 2 | 2009 | 227 | 0.110 |
Why?
| | Gestational Age | 4 | 2015 | 765 | 0.110 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.110 |
Why?
| | HIV | 1 | 2013 | 210 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2674 | 0.100 |
Why?
| | Chlamydia trachomatis | 1 | 1991 | 36 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 1991 | 37 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2015 | 364 | 0.100 |
Why?
| | Prospective Studies | 7 | 2017 | 6471 | 0.100 |
Why?
| | Trophoblasts | 1 | 1993 | 170 | 0.100 |
Why?
| | Peritoneovenous Shunt | 1 | 1990 | 1 | 0.100 |
Why?
| | Maternal-Fetal Exchange | 2 | 2007 | 157 | 0.100 |
Why?
| | Meningitis, Aseptic | 1 | 1990 | 15 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3588 | 0.100 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 1990 | 22 | 0.100 |
Why?
| | Rimantadine | 1 | 2010 | 3 | 0.090 |
Why?
| | Legionnaires' Disease | 1 | 1990 | 4 | 0.090 |
Why?
| | Adamantane | 1 | 2010 | 16 | 0.090 |
Why?
| | Poliovirus | 1 | 1990 | 78 | 0.090 |
Why?
| | Cross Infection | 1 | 1992 | 205 | 0.090 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1774 | 0.090 |
Why?
| | Mice | 8 | 2000 | 15520 | 0.090 |
Why?
| | Meningitis | 1 | 1990 | 74 | 0.090 |
Why?
| | Respiratory Tract Infections | 3 | 2016 | 331 | 0.090 |
Why?
| | Administration, Oral | 3 | 2012 | 756 | 0.090 |
Why?
| | South Africa | 1 | 2009 | 163 | 0.080 |
Why?
| | Maxillary Sinus | 2 | 2009 | 13 | 0.080 |
Why?
| | Age Factors | 4 | 2017 | 2995 | 0.080 |
Why?
| | Mucor | 2 | 2005 | 7 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 709 | 0.080 |
Why?
| | Body Fluids | 1 | 1987 | 62 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2015 | 736 | 0.080 |
Why?
| | Evidence-Based Medicine | 3 | 2021 | 693 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 667 | 0.080 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 81 | 0.070 |
Why?
| | Aspergillosis | 2 | 2014 | 24 | 0.070 |
Why?
| | Virus Diseases | 1 | 2009 | 198 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 79 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2009 | 165 | 0.070 |
Why?
| | Zygomycosis | 1 | 2006 | 6 | 0.070 |
Why?
| | Carotid Artery Thrombosis | 1 | 2005 | 8 | 0.070 |
Why?
| | Chronic Disease | 5 | 2009 | 1636 | 0.070 |
Why?
| | Logistic Models | 2 | 2023 | 1901 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2004 | 1244 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2513 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2007 | 965 | 0.070 |
Why?
| | Animals | 9 | 2000 | 33381 | 0.060 |
Why?
| | International Cooperation | 2 | 2018 | 177 | 0.060 |
Why?
| | Scedosporium | 1 | 2004 | 1 | 0.060 |
Why?
| | Herpesvirus 7, Human | 1 | 2004 | 5 | 0.060 |
Why?
| | Drug Resistance, Fungal | 1 | 2004 | 9 | 0.060 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 6 | 0.060 |
Why?
| | Herpesvirus 6, Human | 1 | 2004 | 13 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2004 | 70 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 2 | 1997 | 48 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 143 | 0.060 |
Why?
| | Vaccines, Conjugate | 2 | 2014 | 63 | 0.060 |
Why?
| | Biological Availability | 1 | 2003 | 126 | 0.060 |
Why?
| | Infant, Premature, Diseases | 2 | 1997 | 93 | 0.060 |
Why?
| | Risk Assessment | 2 | 2020 | 3057 | 0.050 |
Why?
| | Probability | 1 | 2003 | 305 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2000 | 3730 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2015 | 3171 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 77 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 774 | 0.050 |
Why?
| | Bacteria, Aerobic | 1 | 2001 | 7 | 0.050 |
Why?
| | Drug Combinations | 1 | 2022 | 291 | 0.050 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2007 | 468 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2001 | 81 | 0.050 |
Why?
| | Income | 1 | 2022 | 173 | 0.050 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 51 | 0.050 |
Why?
| | Drug Approval | 1 | 2021 | 77 | 0.050 |
Why?
| | Alanine | 1 | 2021 | 102 | 0.050 |
Why?
| | RNA | 2 | 2022 | 833 | 0.050 |
Why?
| | RNA Probes | 2 | 1991 | 14 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 75 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 175 | 0.050 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2000 | 30 | 0.050 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 29 | 0.050 |
Why?
| | Remission Induction | 1 | 2020 | 247 | 0.050 |
Why?
| | Necrosis | 1 | 2000 | 230 | 0.040 |
Why?
| | Amniotic Fluid | 2 | 1991 | 68 | 0.040 |
Why?
| | Fungi | 2 | 2014 | 123 | 0.040 |
Why?
| | Otitis Media with Effusion | 1 | 1999 | 20 | 0.040 |
Why?
| | Pharyngitis | 1 | 1999 | 25 | 0.040 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 93 | 0.040 |
Why?
| | Pseudallescheria | 1 | 1999 | 3 | 0.040 |
Why?
| | Opportunistic Infections | 1 | 1999 | 42 | 0.040 |
Why?
| | Zidovudine | 2 | 2010 | 77 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2005 | 3360 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 6412 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1945 | 0.040 |
Why?
| | Spinal Cord | 1 | 2000 | 367 | 0.040 |
Why?
| | Chlamydiaceae Infections | 1 | 2017 | 1 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2018 | 49 | 0.040 |
Why?
| | Living Donors | 1 | 2020 | 319 | 0.040 |
Why?
| | Sex Factors | 2 | 2017 | 1781 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 1997 | 23 | 0.040 |
Why?
| | B-Lymphocytes | 2 | 2015 | 770 | 0.040 |
Why?
| | Reoperation | 1 | 1999 | 557 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 152 | 0.040 |
Why?
| | Otitis Media | 1 | 1999 | 146 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 1997 | 94 | 0.040 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 248 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 30 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2017 | 181 | 0.040 |
Why?
| | Heart | 1 | 2000 | 631 | 0.040 |
Why?
| | Encephalomyelitis | 1 | 2016 | 9 | 0.040 |
Why?
| | Plasma Cells | 2 | 2009 | 59 | 0.040 |
Why?
| | Acute Disease | 1 | 1999 | 940 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 1997 | 253 | 0.030 |
Why?
| | Immune Tolerance | 2 | 1999 | 334 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2015 | 33 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 52 | 0.030 |
Why?
| | North America | 1 | 2016 | 266 | 0.030 |
Why?
| | Caribbean Region | 1 | 2015 | 24 | 0.030 |
Why?
| | Malnutrition | 1 | 2016 | 66 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 95 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 415 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 1997 | 204 | 0.030 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.030 |
Why?
| | Audiometry | 1 | 2015 | 33 | 0.030 |
Why?
| | Latin America | 1 | 2015 | 74 | 0.030 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 23 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 133 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 122 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 182 | 0.030 |
Why?
| | Coinfection | 1 | 2016 | 119 | 0.030 |
Why?
| | Biopsy | 3 | 2009 | 1079 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 360 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 996 | 0.030 |
Why?
| | Canada | 1 | 2015 | 340 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1995 | 413 | 0.030 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 221 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 133 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 2005 | 1166 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 103 | 0.030 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 55 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 2017 | 265 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 380 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 1993 | 79 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1474 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 299 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2017 | 437 | 0.030 |
Why?
| | Prognosis | 1 | 2001 | 3443 | 0.030 |
Why?
| | Infant, Premature | 1 | 1997 | 480 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 755 | 0.030 |
Why?
| | Electromyography | 1 | 2015 | 326 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2436 | 0.030 |
Why?
| | Epidemiologic Studies | 1 | 2012 | 58 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1355 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 396 | 0.030 |
Why?
| | Oncology Service, Hospital | 1 | 1992 | 14 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2012 | 19 | 0.030 |
Why?
| | Meningococcal Infections | 1 | 2012 | 20 | 0.030 |
Why?
| | Ventilation | 1 | 1992 | 33 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6561 | 0.030 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 12 | 0.030 |
Why?
| | Amniocentesis | 1 | 1991 | 24 | 0.030 |
Why?
| | Europe | 1 | 2012 | 356 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2015 | 1085 | 0.030 |
Why?
| | Microbial Viability | 1 | 2012 | 81 | 0.030 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 24 | 0.030 |
Why?
| | Hospitals, University | 1 | 1991 | 172 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 10 | 0.020 |
Why?
| | Respirovirus Infections | 1 | 1990 | 21 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1067 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1527 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 227 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 65 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 40 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1995 | 1691 | 0.020 |
Why?
| | Benzoxazines | 1 | 2010 | 28 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2010 | 80 | 0.020 |
Why?
| | Inpatients | 1 | 2014 | 388 | 0.020 |
Why?
| | Population Surveillance | 1 | 1993 | 413 | 0.020 |
Why?
| | Legionella | 1 | 1990 | 7 | 0.020 |
Why?
| | Alkynes | 1 | 2010 | 56 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1795 | 0.020 |
Why?
| | Leukemia | 1 | 1992 | 208 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1997 | 4077 | 0.020 |
Why?
| | Dermatomyositis | 1 | 1989 | 22 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3174 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 598 | 0.020 |
Why?
| | Peroxidase | 1 | 2009 | 170 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2009 | 146 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1990 | 143 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2009 | 62 | 0.020 |
Why?
| | Seasons | 1 | 1990 | 461 | 0.020 |
Why?
| | Muscles | 1 | 1989 | 333 | 0.020 |
Why?
| | Picornaviridae | 1 | 1988 | 18 | 0.020 |
Why?
| | Central Nervous System | 1 | 2010 | 245 | 0.020 |
Why?
| | Ribonucleases | 1 | 1987 | 53 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2007 | 27 | 0.020 |
Why?
| | Lamivudine | 1 | 2007 | 59 | 0.020 |
Why?
| | Antigens, CD | 1 | 2009 | 460 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2005 | 16 | 0.020 |
Why?
| | Telencephalon | 1 | 2005 | 17 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4552 | 0.020 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2007 | 156 | 0.020 |
Why?
| | Orbit | 1 | 2005 | 59 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2005 | 64 | 0.020 |
Why?
| | Exocrine Glands | 1 | 2004 | 5 | 0.020 |
Why?
| | Basement Membrane | 1 | 2004 | 32 | 0.020 |
Why?
| | Prevalence | 1 | 2010 | 2326 | 0.010 |
Why?
| | Cell Count | 1 | 2004 | 315 | 0.010 |
Why?
| | Neutrophils | 1 | 2009 | 1233 | 0.010 |
Why?
| | Lymphocytes | 1 | 2004 | 347 | 0.010 |
Why?
| | Eosinophils | 1 | 2004 | 282 | 0.010 |
Why?
| | Macrophages | 1 | 2009 | 1324 | 0.010 |
Why?
| | Penicillin Resistance | 1 | 2001 | 8 | 0.010 |
Why?
| | beta-Lactamases | 1 | 2001 | 26 | 0.010 |
Why?
| | Haemophilus influenzae | 1 | 2001 | 50 | 0.010 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2001 | 63 | 0.010 |
Why?
| | Staphylococcus | 1 | 2001 | 68 | 0.010 |
Why?
| | Drug Resistance, Bacterial | 1 | 2001 | 155 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 9 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 39 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 153 | 0.010 |
Why?
| | Recurrence | 1 | 1999 | 975 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1999 | 465 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 676 | 0.010 |
Why?
| | RNA, Antisense | 1 | 1988 | 19 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 1988 | 42 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 155 | 0.000 |
Why?
| | Aged | 1 | 2006 | 19657 | 0.000 |
Why?
| | Virus Replication | 1 | 1988 | 405 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 27617 | 0.000 |
Why?
| | Cell Line | 1 | 1988 | 2707 | 0.000 |
Why?
| | DNA | 1 | 1988 | 1388 | 0.000 |
Why?
|
|
Abzug's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|